| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AAV2gp07 |
| Uniprot No | A0A513ZUU9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-533aa |
| 氨基酸序列 | MATGSGAPMADNNEGADGVGNSSGNWHCDSTWMGDRVITTSTRTWALPTYNNHLYKQISSQSGASNDNHYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLSFKLFNIQVKEVTQNDGTTTIANNLTSTVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMVPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFTFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTNTPSGTTTMSRLQFSQAGASDIRDQSRNWLPGPCYRQQRVSKTAADNNNSDYSWTGATKYHLNGRDSLVNPGPAMASHKDDEEKYFPQSGVLIFGKQDSGKTNVDIEKVMITDEEEIRTTNPVATEQYGSVSTNLQSGNTQAATSDVNTQGVLPGMVWQDRDVYLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPSTTFSAAKFASFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYNKSVNVDFTVDTNGVYSEPRPIGTRYLTRNL |
| 预测分子量 | 64.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AAV2 gp07重组蛋白的虚构参考文献示例(注：实际文献需通过学术数据库核实)：
---
1. **文献名称**: "Recombinant AAV2 gp07 Protein Enhances Viral Vector Transduction Efficiency"
**作者**: Smith J, et al.
**摘要**: 本研究报道了AAV2 gp07重组蛋白的制备及其在提高rAAV载体转导效率中的作用。通过哺乳动物表达系统纯化的gp07蛋白可结合宿主细胞表面受体，促进病毒颗粒的内化，为基因治疗载体优化提供新策略。
2. **文献名称**: "Structural and Functional Characterization of AAV2 gp07 in Capsid Assembly"
**作者**: Lee H, et al.
**摘要**: 利用冷冻电镜和X射线晶体学解析了AAV2 gp07重组蛋白的三维结构，揭示了其在病毒衣壳组装中的关键作用。实验表明gp07的C端结构域介导了衣壳蛋白的寡聚化，为工程化改造AAV载体提供结构基础。
3. **文献名称**: "AAV2 gp07 Recombinant Protein as a Target for Neutralizing Antibody Analysis"
**作者**: Chen R, et al.
**摘要**: 研究利用重组AAV2 gp07蛋白评估患者血清中的中和抗体水平，发现gp07是免疫反应的主要靶点之一。该蛋白可作为预存免疫监测工具，优化基因治疗中的AAV血清型选择。
4. **文献名称**: "High-Yield Production of AAV2 gp07 in Insect Cell Systems and Its Application in Gene Delivery"
**作者**: Wang Y, et al.
**摘要**: 通过杆状病毒-昆虫细胞系统高效表达AAV2 gp07重组蛋白，优化纯化工艺后获得高纯度产物。体外实验证实其与肝细胞特异性结合，支持其在靶向性基因递送中的应用潜力。
---
如需真实文献，建议在PubMed、Web of Science等平台以关键词“AAV2 recombinant protein”、“AAV2 capsid protein”或“AAV2 gene therapy”检索。
AAV2gp07 recombinant protein is derived from Adeno-Associated Virus serotype 2 (AAV2), a non-pathogenic parvovirus widely used in gene therapy due to its safety profile and ability to infect both dividing and non-dividing cells. The "gp07" designation likely refers to a specific engineered capsid variant or a modified structural component of the AAV2 capsid, optimized for enhanced tissue targeting, reduced immunogenicity, or improved transduction efficiency.
AAV2’s native capsid consists of three viral proteins (VP1. VP2. VP3) that form the icosahedral shell. Recombinant AAV2gp07 is produced by modifying capsid-encoding genes (cap) through techniques like site-directed mutagenesis, peptide insertion, or domain swapping. These modifications aim to overcome limitations of wild-type AAV2. such as low tropism for certain tissues or pre-existing immunity in human populations.
The protein is typically expressed in mammalian or insect cell systems using baculovirus or plasmid transfection, followed by purification via chromatography. Its applications span gene therapy research, particularly in targeting tissues like the liver, retina, or central nervous system. AAV2gp07-based vectors are also explored for delivering CRISPR-Cas9 components, RNA interference agents, or therapeutic transgenes in preclinical studies.
Recent studies focus on optimizing its capsid structure to evade neutralizing antibodies, enhance blood-brain barrier penetration, or enable receptor-specific binding. As a recombinant tool, AAV2gp07 exemplifies the modular engineering of AAVs to balance delivery efficiency with biocompatibility, addressing challenges in precision medicine and regenerative therapies.
×
